title: First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group).
authors.affiliation: Department of Hematology and Oncology, University of Bochum, Marienhospital Herne, Herne, Germany. dirk.strumberg@marienhospital-herne.de
authors.forename: D
authors.initials: D
authors.lastname: Strumberg
authors.forename: L
authors.initials: L
authors.lastname: Bergmann
authors.forename: U
authors.initials: U
authors.lastname: Graeven
authors.forename: A
authors.initials: A
authors.lastname: Hanauske
authors.forename: R
authors.initials: R
authors.lastname: Lipp
authors.forename: J
authors.initials: J
authors.lastname: Schuette
authors.forename: B
authors.initials: B
authors.lastname: Schultheis
authors.forename: P
authors.initials: P
authors.lastname: Scigalla
authors.forename: P
authors.initials: P
authors.lastname: Urrea
authors.forename: M E
authors.initials: ME
authors.lastname: Scheulen
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid